Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 14/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3336553 | 0.99 | NLRP3 (0.37) | NLRP3TP53HSD17B10KDM4EALDH1A1 | |
| SCHEMBL19123170 | 0.91 | SMN1; SMN2 (0.35) | NLRP3TP53KDM4ETSHRMAPT | |
| SCHEMBL13246853 | 0.91 | SMN1; SMN2 (0.35) | NLRP3TP53KDM4ETSHRMAPT | |
| SCHEMBL3337001 | 0.91 | SMN1; SMN2 (0.35) | NLRP3TP53KDM4ETSHRMAPT | |
| Hydrochloric Acid SCHEMBL3339489 | 0.90 | SMN1; SMN2 (0.34) | NLRP3TP53HSD17B10KDM4EALDH1A1 | |
| SCHEMBL2059164 | 0.83 | HDAC6 (0.36) | NLRP3HSD17B10ALDH1A1 | |
| SCHEMBL28774335 | 0.83 | — | — | |
| SCHEMBL12765185 | 0.83 | HDAC6 (0.36) | NLRP3HSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9876601 | 0.81 | HDAC6 (0.35) | NLRP3HSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3339175 | 0.81 | HDAC6 (0.35) | NLRP3HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2202227-B1 | NOVEL HISTIDINE DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2013-11-20 | — | — | EP | disclosed |
| US-8324261-B2 | Histidine derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| EP-2202227-A1 | NOVEL HISTIDINE DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2010-06-30 | — | — | EP | disclosed |
| US-20100152459-A1 | NOVEL HISTIDINE DERIVATIVES | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152459-A1 | NOVEL HISTIDINE DERIVATIVES | HRH4, HNMT, HRH3 | NLRP3 299/4885TP53 4275/4885HSD17B10 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.